8 research outputs found
Study of RPC gas mixtures for the ARGO-YBJ experiment
The ARGO-YBJ experiment consists of a RPC carpet to be operated at the
Yangbajing laboratory (Tibet, P.R. China), 4300 m a.s.l., and devoted to the
detection of showers initiated by photon primaries in the energy range 100 GeV
- 20 TeV. The measurement technique, namely the timing on the shower front with
a few tens of particles, requires RPC operation with 1 ns time resolution, low
strip multiplicity, high efficiency and low single counting rate. We have
tested RPCs with many gas mixtures, at sea level, in order to optimize these
parameters. The results of this study are reported.Comment: 6 pages, 3 figures. To be published in Nucl. Instr. Meth. A, talk
given at the "5th International Workshop on RPCs and Related Detectors", Bari
(Italy) 199
BK virus con riarrangiamento di NCCR nel liquor cefalorachidiano di un paziente con AIDS.
Paraphilic behaviours, autistic traits and gender identity in subjects with Klinefelter syndrome.
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort
Nestmate Recognition and the Role of Cuticular Hydrocarbons in the African Termite Raiding Ant Pachycondyla analis
Incidence of parenterally transmitted acute viral hepatitis among healthcare workers in Italy.
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as switching regimen while virologically suppressed. Primary endpoint was time to treatment failure (TF): new AIDS/death or virological failure (VF) or discontinuation for toxicity/failure. Secondary endpoints were time to treatment discontinuation for toxicity (TDT) and to VF. Groups of interest were those aged >50 years, female sex, and advanced HIV disease at first ART start. Probability of the events overall and according to groups and adjusted HR for every endpoint were calculated by Kaplan-Meier curves and Cox regression models. Results: Nine hundred and thirty-three ART-naive and 1655 ART-experienced PWH initiated BIC/FTC/TAF. Over a median follow-up of 69.8 weeks, 89 (9.6%) PWH at their first regimen experienced TF. PWH aged >50 years had 1.83-fold (95% CI: 1.19-2.83) higher risk of TF; PWH with advanced HIV disease had 2.21-fold (95% CI: 1.53-3.82) higher risk; there were no differences in TF according to sex. Over a median follow-up of 146.3 weeks, 109 (6.6%) out of 1655 switching PWH experienced TF; no differences were found in the risk of TF, TDT and VF according to groups of interest. Conclusions: Overall, BIC/FTC/TAF is well tolerated and virologically effective in the real-world scenario for ART-naive and -experienced PWH. Older ART-naive PWH and those with advanced HIV disease may respond less well as the burden of diseases might compromise treatment efficacy